Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of avelumab as third-line treatment in unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma
2015-003301-42Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Avelumab + best supportive care with Physician’s choice chemotherapy + best supportive care (2 arms). Primary endpoint: Overall survival. Started Feb 2016; status: completed.
02
Drugs
avelumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2015-003301-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003301-42.